Shenyang Sunshine Pharmaceutical Co., Ltd.

The most competitive products: Recombinant Human Erythropoietin Injection (EPIAO), Recombinant Human Interferon Alpha 2a Lyophilized Powder & Injection(INTEFEN), Recombinant Human Interleukin 2 (INLEUSIN).
EPIAO is the leading product in Domestic market. All products are strictly in conformity to EP 2002 standards.

Activity:

- Contract Manufacturing
- Licensing & Business Development
- Research & Development
- Sales & Distribution

Product / Technology type(s) covered:

- API / chemicals
- Bio
- FP (finished products)
- Pharmaceuticals / Therapeutics
- Proteins

Therapeutic targets:

- Cancer
- Hematology
- Infectious Diseases
- Oncology

Markets Covered

a. HeadQuarter: China

b. Continent(s) active: Africa , Near/Middle East , Asia , Central/South America

c. Countries active: Palestine, Brazil, America

Corporate data:

Number of Employees: 300

Turnover:

Amount:	Year:	Currency:
12,000,000	2002	US Dollar

Year founded: 1993

Partners / Alliances: SUNSHIEN cooperates with global partners in two kinds of way:1. Agency for distribution of finished product: Such as in Egypt, Palestine, Vietnam, Indonesia, Malaysia, Pakistan, Sri Lanki and so on. The finished product of rhEPO and Interferon had been launched into Palestine. 2. Supplying of bulk (raw material) and filling locally, such as Iran , Brazil, Chile and so on, 2,000,000 MIU bulk of Interferon alfa-2a is supplied to Brazil annually.